Atomoxetine

Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine

Active ingredient description

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Atomoxetine
N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA09

Medicines

$substanceName is the active ingredient of these drugs:

Drug
Countries

Germany

Hong Kong

Spain

Austria Poland

United Kingdom

Australia

Estonia

Hong Kong

Germany

South Africa

South Africa

Austria Netherlands

Spain

South Africa

Poland

South Africa

South Africa

South Africa

South Africa

Australia Austria Canada Cyprus Ecuador

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 255.355 g/mol

External identifiers

CAS Substance: 83015-26-3
DrugBank Drug: DB00289
KEGG Drug: D07473
RxNorm Ingredient: 38400
SNOMED-CT Concept: 407037005
Atomoxetine (substance)
UNII Identifier: ASW034S0B8
ATOMOXETINE